Predictors of risk for relapse in patients with schizophrenia or schizoaffective disorder during olanzapine drug therapy.

Lipkovich, I; Deberdt, W; Csernansky, J G; Buckley, P; Peuskens, J; Kollack-Walker, S; Zhang, Y; Liu-Seifert, H; Houston, J P

Lipkovich, I; Deberdt, W; Csernansky, J G; Buckley, P; Peuskens, J; Kollack-Walker, S; Zhang, Y; Liu-Seifert, H; Houston, J P.

Affiliation

Lipkovich I; Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, DC 4133, Indianapolis, IN 46285, USA. lipkovichia@lilly.com

J Psychiatr Res ; 41(3-4): 305-10, 2007.

Article in En | MEDLINE | ID: mdl-17010994

Subject(s)

Antipsychotic Agents/therapeutic use; Psychotic Disorders/drug therapy; Risk; Schizophrenia/drug therapy; Adult; Benzodiazepines/therapeutic use; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Middle Aged; Neuropsychological Tests; Olanzapine; Predictive Value of Tests; Proportional Hazards Models; Psychiatric Status Rating Scales; Retrospective Studies; Secondary Prevention

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Psychotic Disorders / Schizophrenia / Antipsychotic Agents / Risk Type of study: Etiology_studies / Evaluation_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Female / Humans / Male / Middle aged Language: En Journal: J Psychiatr Res Year: 2007 Type: Article Affiliation country: United States

Search on Google

XML

PubMed Links